This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): F2695, levomilnacipran extended-release capsules
Description: F2695 is an isomer of milnacipran. F2695 exerts its effects by selectively inhibiting the reuptake of both norepinephrine and serotonin, two neurotransmitters known to play an essential role in regulating mood.
F2695 was originally developed by Pierre Fabre.
Forest and Pierre Fabre
In December 2008, Forest Laboratories and Pierre Fabre Medicament announced that they entered into a definitive collaboration agreement to develop and commercialize F2695 in the United States and Canada.
Under the terms of the agreement, Forest will make an upfront payment to Pierre Fabre of $75 million and will pay future, undisclosed milestone payments. In addition, Pierre Fabre will receive royalty payments based on F2695 sales. Forest will assume responsibility for the clinical development and commercialization of F2695 in the United States and Canada, while Pierre Fabre will fund all preclinical development and drug substance manufacturing activities worldwide.
Forest and Actavis
In February 2014, Actavis and Forest announced that they have entered into a definitive agreement under which Actavis will acquire Forest for a combination of cash and equity valued at...See full deal structure in Biomedtracker
Partners: Pierre Fabre Medicament S.A.
Additional information available to subscribers only: